It includes modulation of sensitivity to sunitinib and PD-1 through activation of the AKT pathway in renal cancer [9], and also generating resistance to trastuzumab through activation of AKT in breast cancer [50]. The gene discussed is AKT1; the disease is breast carcinoma.